1. Home
  2. DMAC vs BNED Comparison

DMAC vs BNED Comparison

Compare DMAC & BNED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$9.69

Market Cap

457.2M

Sector

Health Care

ML Signal

HOLD

Logo Barnes & Noble Education Inc

BNED

Barnes & Noble Education Inc

HOLD

Current Price

$9.08

Market Cap

314.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMAC
BNED
Founded
2000
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Specialty Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
457.2M
314.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DMAC
BNED
Price
$9.69
$9.08
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$15.50
N/A
AVG Volume (30 Days)
529.4K
549.1K
Earning Date
11-12-2025
09-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,567,800,000.00
Revenue This Year
N/A
$2.74
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.19
$5.90
52 Week High
$9.30
$14.41

Technical Indicators

Market Signals
Indicator
DMAC
BNED
Relative Strength Index (RSI) 71.42 58.45
Support Level $7.76 $8.65
Resistance Level $9.23 $9.17
Average True Range (ATR) 0.66 0.49
MACD 0.13 0.16
Stochastic Oscillator 78.29 85.94

Price Performance

Historical Comparison
DMAC
BNED

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About BNED Barnes & Noble Education Inc

Barnes & Noble Education Inc is an operator of bookstores in college and university campuses across the United States. The company is also engaged in providing digital education services. It operates in three reportable segments that include Retail offers existing and prospective clients the flexibility of physical, virtual, or custom store solutions, and wholesale is comprised of the wholesale and virtual retail fulfillment, and support operations of the MBS subsidiary, also Corporate Services represent unallocated shared-service costs which include corporate level expenses and other governance functions, including executive functions, such as accounting, legal, treasury, information technology, and human resources. It earns majority of the revenue from Retail segment.

Share on Social Networks: